A randomized, triple-blinded controlled clinical study with a novel disease-modifying drug combination in equine lameness-associated osteoarthritis

OBJECTIVE: This study aimed to test a novel treatment combination (TC) (equivalent to sildenafil, mepivacaine, and glucose) with disease-modifying properties compared to Celestone® bifas® (CB) in a randomized triple-blinded phase III clinical study in horses with mild osteoarthritis (OA). Joint biom...

Descripción completa

Detalles Bibliográficos
Autores principales: Skiöldebrand, E., Adepu, S., Lützelschwab, C., Nyström, S., Lindahl, A., Abrahamsson-Aurell, K., Hansson, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
ORIGINAL PAPER
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320210/
https://www.ncbi.nlm.nih.gov/pubmed/37416846
http://dx.doi.org/10.1016/j.ocarto.2023.100381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320210/
https://www.ncbi.nlm.nih.gov/pubmed/37416846
http://dx.doi.org/10.1016/j.ocarto.2023.100381

Ejemplares similares